| Guifa Xi,Barbara Mania-Farnell,Ting Lei,Tadanori Tomita. Histone modification as a drug resistance driver in brain tumors. Oncol Transl Med, 2016, 2: 216-226. |
| Histone modification as a drug resistance driver in brain tumors |
| Received:June 16, 2016 Revised:October 11, 2016 |
| View Full Text View/Add Comment Download reader |
| KeyWord:histone modification; drug resistance; brain tumor |
| Author Name | Affiliation | E-mail | | Guifa Xi | Falk Brain Tumor Center, Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL USA | guifa.xi@northwestern.edu | | Barbara Mania-Farnell | Purdue University Calumet, Hammond, IN USA | bmania@pnw.edu | | Ting Lei | Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China | hufeng268@qq.com | | Tadanori Tomita | Northwestern University Feinberg School of Medicine, Chicago, IL USA | ttomita@luriechildrens.org |
|
| Hits: 6961 |
| Download times: 9011 |
| Abstract: |
| Patients with brain tumors, specifically, malignant forms such as glioblastoma, medulloblastoma and ependymoma, exhibit dismal survival rates despite advances in treatment strategies.
Chemotherapeutics, the primary adjuvant treatment for human brain tumors following surgery,
commonly lack efficacy due to either intrinsic or acquired drug resistance. New treatments targeting epigenetic factors are being explored. Post-translational histone modification provides a
critical regulatory platform for processes such as chromosome condensation and segregation,
apoptosis, gene transcription, and DNA replication and repair. This work reviews how aberrant
histone modifications and alterations in histone-modifying enzymes can drive the acquisition of
drug resistance in brain tumors. Elucidating these mechanisms should lead to new treatments
for overcoming drug resistance. |
| Close |
|
|
|